Heteroaryl guanidines; inhibitors of viral replication
    1.
    发明申请
    Heteroaryl guanidines; inhibitors of viral replication 审中-公开
    杂芳基胍; 病毒复制抑制剂

    公开(公告)号:US20060100225A1

    公开(公告)日:2006-05-11

    申请号:US11088276

    申请日:2005-03-23

    摘要: Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A1, R2, R3, R4, R5 and R6 are defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

    摘要翻译: 提供式1化合物及其药学上可接受的形式:其中变量X,Y,Z,A 1,R 2,R 3, R 4,R 5,R 5和R 6在本文中定义。 某些本文所述的具有强抗病毒活性的式1的化合物。 某些化合物1是丙型肝炎病毒复制的有效和/或选择性抑制剂。 还提供了含有一种或多种式1化合物或这些化合物的盐,溶剂化物或酰化前药以及一种或多种药学上可接受的载体,赋形剂或稀释剂的药物组合物。 公开了通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染,特别是HCV感染。 治疗患有感染性疾病的人类患者的方法,还包括治疗其他动物,包括患有传染病的家畜和驯养的伴侣动物的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。

    1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
    2.
    发明授权
    1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands 失效
    1-苯基-4-苄基哌嗪多巴胺受体亚型特异性配体

    公开(公告)号:US07101887B2

    公开(公告)日:2006-09-05

    申请号:US11167735

    申请日:2005-06-27

    IPC分类号: A61K31/495 C07D295/076

    摘要: Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1–C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, alkylthio, hydroxy, amino, mono(C1–C4)alkylamino, di(C1–C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基, 烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4 - )烷基氨基,二(C 1 -C 4 - )烷基氨基或R 2和R 3一起代表一个 与它们所连接的苯环一起形成萘基部分的4碳亚烯基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神病抑郁症和躁狂症。

    Tricyclic aminoalkylcarboxamides; dopamine D.sub.3 receptor subtype
specific ligands
    3.
    发明授权
    Tricyclic aminoalkylcarboxamides; dopamine D.sub.3 receptor subtype specific ligands 失效
    三环氨基烷基酰胺; 多巴胺D3受体亚型特异性配体

    公开(公告)号:US5910586A

    公开(公告)日:1999-06-08

    申请号:US965275

    申请日:1997-11-06

    摘要: Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: R.sub.1 -R.sub.4 represent organic or inorganic groups;A represents an alkylene group of 2 to 6 carbon atoms optionally substituted with one or more, alkyl groups having from 1 to 4 carbon atoms;Y represents methylene, oxygen, sulfur, or NH; andX is either N, C or CH,which compounds are, useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

    摘要翻译: 公开了下式的化合物或其药学上可接受的酸加成盐,其中:R 1 -R 4表示有机或无机基团; A表示任选被一个或多个具有1至4个碳原子的烷基取代的2至6个碳原子的亚烷基; Y表示亚甲基,氧,硫或NH; X是N,C或CH,这些化合物可用于治疗情感障碍如精神分裂症,抑郁症,阿尔茨海默病,运动障碍如帕金森综合征和肌张力障碍,以及其他对多巴胺能阻滞作用的药物滥用 和强迫症。 此外,本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

    1-phenyl-4-benzylpiperazines dopamine receptor subtype
    5.
    发明申请
    1-phenyl-4-benzylpiperazines dopamine receptor subtype 失效
    1-苯基-4-苄基哌嗪多巴胺受体亚型

    公开(公告)号:US20050239799A1

    公开(公告)日:2005-10-27

    申请号:US11167735

    申请日:2005-06-27

    摘要: Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1-C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, alkylthio, hydroxy, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基, 烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4 - )烷基氨基,二(C 1 -C 4 - )烷基氨基或R 2和R 3一起代表一个 与它们所连接的苯环一起形成萘基部分的4碳亚烯基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神病抑郁症和躁狂症。

    1-phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands
    6.
    发明授权
    1-phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands 失效
    1-苯基-4-苄基哌嗪; 多巴胺受体亚型特异性配体

    公开(公告)号:US06172229B2

    公开(公告)日:2001-01-09

    申请号:US09228106

    申请日:1999-01-11

    IPC分类号: C07D295073

    摘要: Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1-C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, alkylthio, hydroxy, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; 并且R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4)烷基氨基,二(C 1 -C 4)烷基氨基或R 2和R 3一起 代表与其所连接的苯环一起形成萘基部分的4碳亚烯基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神抑郁症和躁狂症。

    2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine      .
D.sub4 receptor subtype ligands
    7.
    发明授权
    2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands 失效
    2-芳基-4-(1- [4-杂芳基]哌嗪-1-基)甲基咪唑:多巴胺D4受体亚型配体

    公开(公告)号:US6166205A

    公开(公告)日:2000-12-26

    申请号:US388511

    申请日:1999-09-02

    CPC分类号: C07D401/12 C07D403/12

    摘要: Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: R.sub.a represents ##STR2## where X, Y and Z are the same or different and represent CH or nitrogen;R.sub.1 R.sub.2, R.sub.3 and R.sub.4 independently represent organic or inorganic groups; andR.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen,which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

    摘要翻译: 公开了下式的化合物或其药学上可接受的酸加成盐,其中:R a表示其中X,Y和Z相同或不同,表示CH或氮; R1R2,R3和R4独立地表示有机或无机基团; R5是氢,C1-C6烷基或卤素,这些化合物可用于治疗和/或预防神经心理障碍,包括但不限于精神分裂症,躁狂症,痴呆,抑郁症,焦虑症,强迫行为,药物滥用,帕金森病 类运动障碍和与使用精神安定药有关的运动障碍。

    1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
    8.
    发明授权
    1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands 失效
    1-苯基-4-苄基哌嗪:多巴胺受体亚型特异性配体

    公开(公告)号:US5859246A

    公开(公告)日:1999-01-12

    申请号:US791673

    申请日:1997-01-30

    摘要: Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable addition salts thereof wherein: R.sub.1 is halogen or C.sub.1 -C.sub.4 alkyl; andR.sub.2 and R.sub.3 are the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, alkylthio, hydroxy, amino, mono(C.sub.1 -C.sub.4)alkylamino, di(C.sub.1 -C.sub.4)alkylamino, orR.sub.2 and R.sub.3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety,which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; 并且R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4)烷基氨基,二(C 1 -C 4)烷基氨基或R 2和 R3一起代表一个4碳亚烯基部分,与它们所连接的苯环一起形成萘基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神抑郁症和躁狂症。

    1-phenyl-4-benzlpiperazines: dopamine receptor subtype specific ligands
    9.
    发明授权
    1-phenyl-4-benzlpiperazines: dopamine receptor subtype specific ligands 失效
    1-苯基-4-苯并哌嗪:多巴胺受体亚型特异性配体

    公开(公告)号:US06656943B2

    公开(公告)日:2003-12-02

    申请号:US10186235

    申请日:2002-06-28

    IPC分类号: A61K31495

    摘要: Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1-C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, alkylthio, hydroxy, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; 并且R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4)烷基氨基,二(C 1 -C 4)烷基氨基或R 2和R 3一起 代表与其所连接的苯环一起形成萘基部分的4碳亚烯基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神抑郁症和躁狂症。

    1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
    10.
    发明授权
    1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands 失效
    1-苯基-4-苄基哌嗪多巴胺受体亚型特异性配体

    公开(公告)号:US06426347B2

    公开(公告)日:2002-07-30

    申请号:US09736566

    申请日:2000-12-13

    IPC分类号: C07D295073

    摘要: Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R1 is halogen or C1-C4 alkyl; and R2 and R3 are the same or different and represent hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, alkylthio, hydroxy, amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, or R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

    摘要翻译: 公开了下式的化合物或其药学上可接受的加成盐,其中:R 1是卤素或C 1 -C 4烷基; 并且R 2和R 3相同或不同,表示氢,卤素,C 1 -C 4烷基,C 1 -C 4烷氧基,烷硫基,羟基,氨基,单(C 1 -C 4)烷基氨基,二(C 1 -C 4)烷基氨基或R 2和R 3一起 代表与其所连接的苯环一起形成萘基部分的4碳亚烯基部分,该化合物可用于治疗神经疾病疾病如精神分裂症,精神抑郁症和躁狂症。